Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine versus azacitidine + vorinostat for relapsed acute myeloid leukemia in patients unfit for intensive chemotherapy
ISRCTN68224706Phase 2Completed
- Sponsor
- University of Birmingham
- Start
- Sep 2012
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, open-label trial of azacitidine and vorinostat in acute myeloid leukemia (AML), sponsored by University of Birmingham. Started Sep 2012; status: completed.
02
Drugs
azacitidinevorinostat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ISRCTN68224706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN68224706.